Chlamydia pneumoniae

Image:Chlamydophila pneumoniae lifecycle-it.svg

Chlamydia pneumoniae is a small gram-negative bacterium (0.2 to 1 μm) that undergoes several transformations during its life cycle. It exists as an elementary body (EB) between hosts. The EB is not biologically active, but is resistant to environmental stresses and can survive outside a host for a limited time. The EB travels from an infected person to the lungs of an uninfected person in small droplets and is responsible for infection. Once in the lungs, the EB is taken up by cells in a pouch called an endosome by a process called phagocytosis. However, the EB is not destroyed by fusion with lysosomes, as is typical for phagocytosed material. Instead, it transforms into a reticulate body (RB) and begins to replicate within the endosome. The reticulate bodies must use some of the host's cellular metabolism to complete its replication. The reticulate bodies then convert back to elementary bodies and are released back into the lung, often after causing the death of the host cell. The EBs are thereafter able to infect new cells, either in the same organism or in a new host. Thus, the lifecycle of C. pneumoniae is divided between the elementary body, which is able to infect new hosts but cannot replicate, and the reticulate body, which replicates but is not able to cause a new infection.{{cite web |url=https://www.lecturio.com/concepts/chlamydial-infections/ | title=Chlamydial Infections

|website=The Lecturio Medical Concept Library |access-date= 8 July 2021}}

{{see also|Asthma-related microbes}}

Chlamydia pneumoniae is a common cause of pneumonia around the world; it is typically acquired by otherwise-healthy people and is a form of community-acquired pneumonia. Its treatment and diagnosis are different from historically recognized causes, such as Streptococcus pneumoniae.{{cite journal | vauthors = Pignanelli S, Shurdhi A, Delucca F, Donati M | title = Simultaneous use of direct and indirect diagnostic techniques in atypical respiratory infections from Chlamydophila pneumoniae and Mycoplasma pneumoniae | journal = Journal of Clinical Laboratory Analysis | volume = 23 | issue = 4 | pages = 206–9 | year = 2009 | pmid = 19623657 | doi = 10.1002/jcla.20332 | pmc = 6648992 }} Because it does not gram stain well, and because C. pneumoniae bacteria is very different from the many other bacteria causing pneumonia (in the earlier days, it was even thought to be a virus), the pneumonia caused by C. pneumoniae is categorized as an "atypical pneumonia".{{cite journal |author=Cunha BA |title=The atypical pneumonias: clinical diagnosis and importance |journal=Clin. Microbiol. Infect. |volume=12 |issue=Suppl 3 |pages=12–24 |date=May 2006 |pmid=16669925 |doi=10.1111/j.1469-0691.2006.01393.x |pmc=7128183 }}

One meta-analysis of serological data comparing prior C. pneumoniae infection in patients with and without lung cancer found results suggesting prior infection was associated with an increased risk of developing lung cancer.{{cite journal | vauthors = Zhan P, Suo LJ, Qian Q, Shen XK, Qiu LX, Yu LK, Song Y | title = Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis | journal = European Journal of Cancer | volume = 47 | issue = 5 | pages = 742–7 | date = March 2011 | pmid = 21194924 | doi = 10.1016/j.ejca.2010.11.003 }}{{cite journal | vauthors = Mager DL | title = Bacteria and cancer: cause, coincidence or cure? A review | journal = Journal of Translational Medicine | volume = 4 | pages = 14 | year = 2006 | pmid = 16566840 | pmc = 1479838 | doi = 10.1186/1479-5876-4-14 | doi-access = free }}{{cite journal | vauthors = Littman AJ, Jackson LA, Vaughan TL | title = Chlamydia pneumoniae and lung cancer: epidemiologic evidence | journal = Cancer Epidemiology, Biomarkers & Prevention | volume = 14 | issue = 4 | pages = 773–8 | date = April 2005 | pmid = 15824142 | doi = 10.1158/1055-9965.EPI-04-0599 | s2cid = 6510957 | doi-access = }}

In research into the association between C. pneumoniae infection and atherosclerosis and coronary artery disease, serological testing, direct pathologic analysis of plaques, and in vitro testing suggest infection with C. pneumoniae is a significant risk factor for development of atherosclerotic plaques and atherosclerosis.{{cite journal | vauthors = Kälvegren H, Bylin H, Leanderson P, Richter A, Grenegård M, Bengtsson T | title = Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins | journal = Thrombosis and Haemostasis | volume = 94 | issue = 2 | pages = 327–35 | date = August 2005 | pmid = 16113822 | doi = 10.1160/TH04-06-0360 | s2cid = 6103162 }} C. pneumoniae infection increases adherence of macrophages to endothelial cells in vitro and aortas ex vivo.{{cite journal | vauthors = Takaoka N, Campbell LA, Lee A, Rosenfeld ME, Kuo CC | title = Chlamydia pneumoniae infection increases adherence of mouse macrophages to mouse endothelial cells in vitro and to aortas ex vivo | journal = Infection and Immunity | volume = 76 | issue = 2 | pages = 510–4 | date = February 2008 | pmid = 18070891 | pmc = 2223438 | doi = 10.1128/IAI.01267-07 }} However, most current research and data are insufficient and do not define how often C. pneumoniae is found in atherosclerotic or normal vascular tissue.{{cite journal | vauthors = Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C | title = Chlamydia pneumoniae and vascular disease: an update | journal = Journal of Vascular Surgery | volume = 43 | issue = 6 | pages = 1301–7 | date = June 2006 | pmid = 16765261 | doi = 10.1016/j.jvs.2006.02.050 | doi-access = free }}

Chlamydia pneumoniae has also been found in the cerebrospinal fluid of patients diagnosed with multiple sclerosis.{{cite journal | vauthors = Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM | title = Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis | journal = Annals of Neurology | volume = 46 | issue = 1 | pages = 6–14 | date = July 1999 | pmid = 10401775 | doi = 10.1002/1531-8249(199907)46:1<6::AID-ANA4>3.0.CO;2-M | s2cid = 29779286 }}

Chlamydia pneumoniae infection was first associated with wheezing, asthmatic bronchitis, and adult-onset asthma in 1991.{{cite journal | vauthors = Hahn DL, Dodge RW, Golubjatnikov R | title = Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma | journal = JAMA | volume = 266 | issue = 2 | pages = 225–30 | date = July 1991 | pmid = 2056624 | doi = 10.1001/jama.266.2.225 }} Subsequent studies of bronchoalveolar lavage fluid from pediatric patients with asthma and also other severe chronic respiratory illnesses have demonstrated that over 50 percent had evidence of C. pneumoniae by direct organism identification.{{cite journal | vauthors = Schmidt SM, Müller CE, Bruns R, Wiersbitzky SK | title = Bronchial Chlamydia pneumoniae infection, markers of allergic inflammation and lung function in children | journal = Pediatric Allergy and Immunology | volume = 12 | issue = 5 | pages = 257–65 | date = October 2001 | pmid = 11737672 | doi = 10.1034/j.1399-3038.2001.00042.x | s2cid = 43107174 }}{{cite journal | vauthors = Webley WC, Salva PS, Andrzejewski C, Cirino F, West CA, Tilahun Y, Stuart ES | title = The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia | journal = American Journal of Respiratory and Critical Care Medicine | volume = 171 | issue = 10 | pages = 1083–8 | date = May 2005 | pmid = 15735056 | doi = 10.1164/rccm.200407-917OC }} C. pneumoniae infection triggers acute wheezing, if it becomes chronic then it is diagnosed as asthma.{{cite journal | vauthors = Hahn DL, McDonald R | title = Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? | journal = Annals of Allergy, Asthma & Immunology | volume = 81 | issue = 4 | pages = 339–44 | date = October 1998 | pmid = 9809498 | doi = 10.1016/S1081-1206(10)63126-2 }} These observations suggest that acute C. pneumoniae infection is capable of causing protean manifestations of chronic respiratory illness which lead to asthma.{{cite journal|vauthors = Webley WC, Hahn DL | title = Infection-mediated asthma: Etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides | journal = Respiratory Research | volume = 18 | issue = 1 | date = 2017 | page = 98 | pmid = 28526018 |doi = 10.1186/s12931-017-0584-z | pmc = 5437656 | doi-access = free }}

Macrolide antibiotic treatment can improve asthma in a subgroup of patients that remains to be clearly defined. Macrolide benefits were first suggested in two observational trials{{cite journal | vauthors = Hahn DL | title = Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial | journal = The Journal of Family Practice | volume = 41 | issue = 4 | pages = 345–51 | date = October 1995 | pmid = 7561707 | url = http://go.galegroup.com/ps/anonymous?id=GALE%7CA17527968 }}{{cite journal | vauthors = Hahn DL, Schure A, Patel K, Childs T, Drizik E, Webley W | title = Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity | journal = PLOS ONE | volume = 7 | issue = 4 | pages = e35945 | year = 2012 | pmid = 22545149 | pmc = 3335830 | doi = 10.1371/journal.pone.0035945 | bibcode = 2012PLoSO...735945H | doi-access = free }} and two randomized controlled trials{{cite journal | vauthors = Hahn DL, Plane MB, Mahdi OS, Byrne GI | title = Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma | journal = PLOS Clinical Trials | volume = 1 | issue = 2 | pages = e11 | date = June 2006 | pmid = 16871333 | pmc = 1488900 | doi = 10.1371/journal.pctr.0010011 | doi-access = free }}{{cite journal | vauthors = Hahn DL, Grasmick M, Hetzel S, Yale S | title = Azithromycin for bronchial asthma in adults: an effectiveness trial | journal = Journal of the American Board of Family Medicine | volume = 25 | issue = 4 | pages = 442–59 | year = 2012 | pmid = 22773713 | doi = 10.3122/jabfm.2012.04.110309 | doi-access = free }} of azithromycin treatment for asthma. One of these RCTs and another macrolide trial{{cite journal | vauthors = Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG | title = Clarithromycin targets neutrophilic airway inflammation in refractory asthma | journal = American Journal of Respiratory and Critical Care Medicine | volume = 177 | issue = 2 | pages = 148–55 | date = January 2008 | pmid = 17947611 | doi = 10.1164/rccm.200707-1134OC | citeseerx = 10.1.1.318.5663 }} suggest that the treatment effect may be greatest in patients with severe, refractory asthma. These clinical results correlate with epidemiological evidence that C. pneumoniae is positively associated with asthma severity{{cite journal | vauthors = Von HL, Vasankari T, Liippo K, Wahlström E, Puolakkainen M | title = Chlamydia pneumoniae and severity of asthma | journal = Scandinavian Journal of Infectious Diseases | volume = 34 | issue = 1 | pages = 22–7 | year = 2002 | pmid = 11874160 | doi = 10.1080/00365540110077155 | s2cid = 21900343 }} and laboratory evidence that C. pneumoniae infection creates steroid-resistance.{{cite journal | vauthors = Cho YS, Kim TB, Lee TH, Moon KA, Lee J, Kim YK, Lee KY, Moon HB | title = Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway | journal = Clinical and Experimental Allergy | volume = 35 | issue = 12 | pages = 1625–31 | date = December 2005 | pmid = 16393329 | doi = 10.1111/j.1365-2222.2005.02391.x | s2cid = 84290541 | doi-access = free }} A meta analysis of 12 RCTs of macrolides for the long term management of asthma found significant effects on asthma symptoms, quality of life, bronchial hyper reactivity and peak flow but not FEV1.{{cite journal | vauthors = Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, Colin AA, Quizon A, Forno E | title = Macrolides for the long-term management of asthma--a meta-analysis of randomized clinical trials | journal = Allergy | volume = 68 | issue = 8 | pages = 1040–9 | date = August 2013 | pmid = 23895667 | doi = 10.1111/all.12199 | s2cid = 17057866 }} More recent positive results of long-term treatment with azithromycin on asthma exacerbations and quality-of-life in patients with severe, refractory asthma{{cite journal |last1=Gibson |first1=PG |title=Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial |journal=Lancet |date=2017 |volume=390 |issue=10095 |pages=659–668 |doi=10.1016/S0140-6736(17)31281-3|pmid=28687413 |s2cid=4523731 }}{{cite journal |last1=Gibson |first1=PG |title=Efficacy of azithromycin in severe asthma from the AMAZES randomised trial |journal=ERJ Open Res |date=2019 |volume=5 |issue=4 |pages=00056–2019 |doi=10.1183/23120541.00056-2019 |pmid=31886156 |pmc=6926362 }} have resulted in azithromycin now being recommended in international guidelines as a treatment option for these types of patients.{{cite web |last1=GINA |title=Difficult-to-Treat and Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management |url=https://ginasthma.org/severeasthma/ |website=Global Initiative for Asthma |access-date=August 1, 2021}}

A recent case series of 101 adults with asthma reported that macrolides (mostly azithromycin) and tetracyclines, either separately or in combination, appeared to be dramatically efficacious in a subgroup of "difficult-to-treat" (i.e., not necessarily refractory to high-dose inhaled corticosteroids but who did not take them) patients with severe asthma, many of whom also had the "overlap syndrome" (asthma and COPD).{{cite journal |last1=Wagshul |first1=FA |title=Outcomes of Antibiotics in Adults with "Difficult to Treat" Asthma or the Overlap Syndrome |journal=J Asthma Allergy |date=2021 |volume=14 |pages=703–712 |pmid=34163182 | doi=10.2147/JAA.S313480|pmc=8216074 |doi-access=free }} Randomized, controlled trials that include these types of asthma patients are needed.

Chlamydia pneumoniae infection has been associated with schizophrenia.{{cite journal | vauthors = Arias I | title = Infectious agents associated with schizophrenia: a meta-analysis. | journal = Schizophr. Res. | volume = 136 | issue = 1–3 | pages = 128–136 | date = April 2012 | pmid = 22104141 | doi = 10.1016/j.schres.2011.10.026 | s2cid = 2687441 | hdl = 10481/90076 | hdl-access = free }} Many other pathogens have been associated with schizophrenia as well. Chronic Chlamydia pneumoniae infection has also in some cases been found to be a cause of chronic fatigue syndrome (CFS) that can be resolved with antibiotics.{{cite journal | vauthors = Kavyani B, Lidbury BA, Schloeffel R, Fisher PR, Missailidis D, Annesley SJ, Dehhaghi M, Heng B, Guillemin GJ | title = Could the kynurenine pathway be the key missing piece of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) complex puzzle? | journal = Cell Mol Life Sci | volume = 79 | issue = 8 | pages = 412 | date = July 2022 | pmid = 35821534| pmc = 9276562 | doi = 10.1007/s00018-022-04380-5 | url = }}{{cite journal | vauthors = Chia JK, Chia LY | title = Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome | journal = Clin Infect Dis | volume = 29 | issue = 2 | pages = 452–453 | date = August 1999 | pmid = 10476765 | doi = 10.1086/520239 | url = }}

The first-line antibiotics for treatment of Chlamydia pneumoniae are the macrolide erythromycin and the tetracyclines tetracycline and doxycycline.{{cite journal | vauthors = Burillo A, Bouza E | title = Chlamydophila pneumoniae | journal = Infect Dis Clin North Am | volume = 24 | issue = 1 | pages = 61–71 | date = March 2010 | pmid = 20171546 | doi = 10.1016/j.idc.2009.10.002 | url = }} The macrolides clarithromycin and azithromycin are also effective. Chlamydia pneumoniae shows resistance to penicillin, ampicillin, and sulfa drugs, and hence these antibiotics are not recommended. Other antibiotics which may be effective include fluoroquinolones like levofloxacin, gatifloxacin, gemifloxacin, and moxifloxacin. Symptoms of Chlamydia pneumoniae often reappear after short or conventional courses of antibiotics. As a result, following confirmation of persistent infection with culture, intensive long-term treatment is recommended.

There is currently no vaccine to protect against Chlamydia pneumoniae. Identification of immunogenic antigens is critical for the construction of an efficacious subunit vaccine against C. pneumoniae infections. Additionally, there is a general shortage worldwide of facilities that can identify/diagnose Chlamydia pneumoniae.{{cn|date=November 2022}}

{{Reflist|30em}}

{{Portal|Medicine}}

• [http://www.cpnhelp.org/recentobservations Chlamydia Pneumoniae cpnhelp.org] {{Webarchive|url=https://web.archive.org/web/20220705183539/https://cpnhelp.org/recentobservations |date=2022-07-05 }}
• [https://bacdive.dsmz.de/strain/2394 Type strain of Chlamydopila pneumoniae at BacDive - the Bacterial Diversity Metadatabase]

{{Gram-negative non-proteobacterial bacterial diseases}}

{{Taxonbar|from=Q132319}}

{{Authority control}}

Category:Chlamydiota

Category:Infectious causes of cancer